Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

bright-gene.com

Founded Year

2001

Stage

IPO | IPO

Total Raised

$80.28M

Date of IPO

11/8/2019

About BrightGene Bio-Medical Technology

BrightGene Bio-Medical Technology is a biopharmaceutical company that engages in the research, development, and manufacturing of high-value generics, such as complex Active Pharmaceutical Ingredients (API) and Intermediates.

BrightGene Bio-Medical Technology Headquarters Location

Building C25-C31, No. 218 Xinghu Road Suzhou Industrial Park

Suzhou, Jiangsu, 215123,

China

+86 0512-62620988

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing BrightGene Bio-Medical Technology

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned BrightGene Bio-Medical Technology in 1 CB Insights research brief, most recently on Nov 11, 2019.

BrightGene Bio-Medical Technology Patents

BrightGene Bio-Medical Technology has filed 16 patents.

The 3 most popular patent topics include:

  • Experimental cancer drugs
  • Transcription factors
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/19/2018

12/7/2021

Polysaccharides, Sugar substitutes, Carbohydrates, Carbohydrate chemistry, Food additives

Grant

Application Date

4/19/2018

Grant Date

12/7/2021

Title

Related Topics

Polysaccharides, Sugar substitutes, Carbohydrates, Carbohydrate chemistry, Food additives

Status

Grant

Latest BrightGene Bio-Medical Technology News

Chinese firms approved to make Merck’s Covid-19 pills for poor countries

Jan 21, 2022

Five Chinese companies are now allowed to make cheap versions of Merck’s Covid-19 pills to supply low-income countries, an UN-backed organisation said on Thursday.Shanghai Fosun Pharmaceutical, BrightGene Bio-Medical Technology, Shanghai Desano Pharmaceuticals and Lonzeal Pharmaceuticals have permission to produce both the raw ingredients and finished product of the oral antiviral medicine molnupiravir, the Medicines Patent Pool (MPP) said on Thursday.Langhua Pharmaceutical is permitted to make…

BrightGene Bio-Medical Technology Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

BrightGene Bio-Medical Technology Rank

  • When was BrightGene Bio-Medical Technology founded?

    BrightGene Bio-Medical Technology was founded in 2001.

  • Where is BrightGene Bio-Medical Technology's headquarters?

    BrightGene Bio-Medical Technology's headquarters is located at Building C25-C31, No. 218 Xinghu Road, Suzhou.

  • What is BrightGene Bio-Medical Technology's latest funding round?

    BrightGene Bio-Medical Technology's latest funding round is IPO.

  • How much did BrightGene Bio-Medical Technology raise?

    BrightGene Bio-Medical Technology raised a total of $80.28M.

  • Who are the investors of BrightGene Bio-Medical Technology?

    Investors of BrightGene Bio-Medical Technology include GF Qianhe, Sequoia Capital China, HighLight Capital, Rongda Microloan, Tririver Capital and 9 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.